Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Xencor, Inc. (NASDAQ:XNCR) have been assigned an average recommendation of “Buy” from the eight brokerages that are covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $34.38.

XNCR has been the subject of a number of recent analyst reports. StockNews.com lowered shares of Xencor from a “hold” rating to a “sell” rating in a research report on Friday, March 14th. Wells Fargo & Company reduced their target price on Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. Finally, Piper Sandler upgraded Xencor from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $20.00 to $30.00 in a research note on Monday, December 2nd.

Xencor Stock Down 2.4 %

Shares of NASDAQ XNCR opened at $11.23 on Tuesday. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The company has a market cap of $791.29 million, a P/E ratio of -3.51 and a beta of 0.74. Xencor has a 52 week low of $10.90 and a 52 week high of $27.24. The business has a 50-day simple moving average of $15.56 and a two-hundred day simple moving average of $20.09.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.19. The company had revenue of $52.79 million during the quarter, compared to analyst estimates of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. Research analysts anticipate that Xencor will post -3.68 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Xencor

Large investors have recently modified their holdings of the company. Sanctuary Advisors LLC bought a new position in Xencor during the third quarter valued at approximately $540,000. Barclays PLC boosted its stake in shares of Xencor by 100.7% in the 3rd quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company’s stock valued at $3,128,000 after purchasing an additional 78,066 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Xencor in the 3rd quarter valued at $362,000. Jane Street Group LLC grew its holdings in shares of Xencor by 18.6% during the 3rd quarter. Jane Street Group LLC now owns 168,431 shares of the biopharmaceutical company’s stock valued at $3,387,000 after purchasing an additional 26,473 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in Xencor by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,455,350 shares of the biopharmaceutical company’s stock worth $29,273,000 after purchasing an additional 17,658 shares during the period.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.